Amalgamated Bank Grows Position in ICU Medical, Inc. (NASDAQ:ICUI)

Amalgamated Bank raised its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 13.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,067 shares of the medical instruments supplier’s stock after buying an additional 816 shares during the quarter. Amalgamated Bank’s holdings in ICU Medical were worth $1,288,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Hexagon Capital Partners LLC grew its holdings in shares of ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 122 shares in the last quarter. Allworth Financial LP grew its holdings in shares of ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 100 shares in the last quarter. Innealta Capital LLC purchased a new stake in shares of ICU Medical during the second quarter worth $32,000. Motco purchased a new stake in shares of ICU Medical in the first quarter valued at about $29,000. Finally, EntryPoint Capital LLC grew its holdings in shares of ICU Medical by 731.5% in the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 395 shares during the period. Hedge funds and other institutional investors own 96.10% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on ICUI shares. Raymond James upped their price objective on shares of ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a report on Thursday, September 12th. Jefferies Financial Group started coverage on shares of ICU Medical in a report on Monday, October 14th. They issued a “hold” rating and a $183.00 price objective for the company. Needham & Company LLC reissued a “hold” rating on shares of ICU Medical in a report on Wednesday. KeyCorp upped their price objective on shares of ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday. Finally, StockNews.com lowered shares of ICU Medical from a “buy” rating to a “hold” rating in a report on Tuesday. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $173.00.

Insider Transactions at ICU Medical

In other news, VP Daniel Woolson sold 2,502 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the sale, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, CEO Vivek Jain sold 12,000 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the sale, the chief executive officer now owns 104,593 shares of the company’s stock, valued at approximately $17,096,771.78. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares in the company, valued at approximately $2,139,324.54. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,502 shares of company stock valued at $8,445,976. 6.70% of the stock is currently owned by corporate insiders.

ICU Medical Trading Down 1.8 %

NASDAQ ICUI opened at $174.81 on Thursday. The firm’s 50-day moving average is $176.11 and its two-hundred day moving average is $141.98. ICU Medical, Inc. has a 12 month low of $82.82 and a 12 month high of $196.26. The company has a debt-to-equity ratio of 0.76, a current ratio of 2.41 and a quick ratio of 1.08. The stock has a market capitalization of $4.27 billion, a P/E ratio of -38.25 and a beta of 0.66.

ICU Medical (NASDAQ:ICUI) last posted its earnings results on Tuesday, November 12th. The medical instruments supplier reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.35. ICU Medical had a negative net margin of 4.74% and a positive return on equity of 5.04%. The company had revenue of $580.07 million for the quarter, compared to analysts’ expectations of $574.77 million. On average, sell-side analysts anticipate that ICU Medical, Inc. will post 3.81 earnings per share for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.